Lonza’s full-year core EBITDA up 20.7% on vaccine demand
By Ludwig Burger -Swiss drug contract manufacturer Lonza said core earnings gained 20.7% in 2021, shored up by demand for the substances it supplies for new mRNA COVID-19 vaccines. Full-year core earnings…